Your browser doesn't support javascript.
loading
Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth.
Eckard, Allison Ross; Thierry-Palmer, Myrtle; Silvestrov, Natalia; Rosebush, Julia C; O'Riordan, Mary Ann; Daniels, Julie E; Uribe-Leitz, Monika; Labbato, Danielle; Ruff, Joshua H; Singh, Ravinder J; Tangpricha, Vin; McComsey, Grace A.
Afiliação
  • Eckard AR; Medical University of South Carolina, Charleston, SC, United States; Emory University School of Medicine, Atlanta, GA, United States. Electronic address: eckarda@musc.edu.
  • Thierry-Palmer M; Morehouse School of Medicine, Atlanta, GA, United States.
  • Silvestrov N; Morehouse School of Medicine, Atlanta, GA, United States.
  • Rosebush JC; Emory University School of Medicine, Atlanta, GA, United States.
  • O'Riordan MA; Case Western Reserve University Cleveland, OH, United States.
  • Daniels JE; Emory University School of Medicine, Atlanta, GA, United States.
  • Uribe-Leitz M; Emory University School of Medicine, Atlanta, GA, United States.
  • Labbato D; Case Western Reserve University Cleveland, OH, United States.
  • Ruff JH; Emory University School of Medicine, Atlanta, GA, United States.
  • Singh RJ; Mayo Clinic, Rochester, MN, United States.
  • Tangpricha V; Emory University School of Medicine, Atlanta, GA, United States.
  • McComsey GA; Case Western Reserve University Cleveland, OH, United States.
J Steroid Biochem Mol Biol ; 168: 38-48, 2017 04.
Article em En | MEDLINE | ID: mdl-28161530
Vitamin D insufficiency is widespread in HIV-infected patients. HIV and/or antiretroviral therapy (ART), particularly efavirenz (EFV), may interfere with vitamin D metabolism. However, few data from randomized, controlled trials exist. Here, we investigate changes in vitamin D metabolites and binding protein (VDBP) after 6 months of supplementation in a randomized, active-control, double-blind trial investigating 2 different monthly cholecalciferol (vitamin D3) doses [60,000 (medium) or 120,000 (high) IU/month] vs. a control arm of 18,000 IU/month in 8-25year old HIV-infected youth on ART with HIV-1 RNA <1000 copies/mL and baseline 25-hydroxycholecalciferol (25(OH)D3) ≤30ng/mL. A matched healthy uninfected group was enrolled in a similar parallel study for comparison. Changes after 6 months were analyzed as intent-to-treat within/between groups [control group (low dose) vs. combined supplementation doses (medium+high)]. At 6 months, 55% vs. 82% of subjects in control and supplementation groups, respectively, reached 25(OH)D3 ≥30ng/mL (P=0.01) with no difference between medium and high doses (both 82% ≥30ng/mL). There were few differences for those on EFV vs. no-EFV, except serum VDBP decreased in EFV-treated subjects (both within- and between-groups P≤0.01). There were no significant differences between the HIV-infected vs. healthy uninfected groups. The major finding of the present study is that cholecalciferol supplementation (60,000 or 120,000 IU/month) effectively raises serum 25(OH)D3 in the majority of HIV-infected subjects, regardless of EFV use. Notably, response to supplementation was similar to that of uninfected subjects.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vitamina D / Proteína de Ligação a Vitamina D / Infecções por HIV / Colecalciferol Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vitamina D / Proteína de Ligação a Vitamina D / Infecções por HIV / Colecalciferol Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article